INSEMA reports its omission of SLNB data - presented by Dr. Toralf Reimer: rates of positive SLN 15% in SLN arm with no differences in oncologic outcomes, adding to the growing body of literature suggesting the safety of this approach #SABCS24
COMET PROs presented by Dr. Ann Partridge - no differences seen in cancer worry, similar quality of life to date #SABCS24
Highly anticipated first results of the COMET trial presented by Dr. Shelley Hwang @sabcs.bsky.social — early oncologic outcomes promising, with significant crossover into the active surveillance arm suggesting significant interest in this approach #SABCS24
SUPREMO 10 yr outcomes from Dr. Ian Kunkler — no benefit to RT in this intermediate risk population. Of note, all N+ got ALND and RNI was not used, so results do not necessarily reflect current practice with increasing omission of ALND for low volume nodal disease #SABCS
EUROPA trial presented by Dr @icromeattini.bsky.social - RT alone offers better HRQoL over ET alone in luminal early BC in pts 70+, with no oncologic events at 24mo in the interim analysis #SABCS24
Wonderful poster discussion by @drsarahsammons.bsky.social of @dfcibreastonc.bsky.social summarizing the interesting and important studies on immune toxicity in breast cancer @sabcs.bsky.social #SABCS24
Headed to #SABCS24 @sabcs.bsky.social ! ✈️
My picks for top 5 locoregional abstracts I’m looking forward to with some implications for practice changes:
Trying out this 🦋 thing!
Academic breast surgeon here #surgsky #medsky #oncsky, passionate about teaching the next generation of surgeons #surged #meded, research and clinical trials, and #equity
Thankful for the freedom to choose… at least social medial platforms.
Happy Thanksgiving all!
